Neola Medical AB (OSTO:NEOLA) EBIT: kr-11.09 Mil (TTM As of Dec. 2025)


OSTO:NEOLA Neola Medical AB OSTO:NEOLA
29 GF Score
Price kr0.92
! 1 Warning Sign
View Full Analysis

What is Neola Medical AB EBIT?

Neola Medical AB OSTO:NEOLA +0.55% 29 EBIT is kr-11.09 Mil as of Dec. 2025. GuruFocus rates OSTO:NEOLA with a GF Score™ of 29/100. The stock has 1 warning sign investors should review.

Neola Medical AB's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2025 was kr-2.52 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was kr-11.09 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Neola Medical AB's annualized ROC % for the quarter that ended in Dec. 2025 was -15.91%. Neola Medical AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -4,550.79%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Neola Medical AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -19.09%.

Neola Medical AB  (OSTO:NEOLA) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Neola Medical AB's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-10.08 * ( 1 - 0% )/( (63.491 + 63.233)/ 2 )
=-10.08/63.362
=-15.91 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=82.614 - 0 - ( 22.123 - max(0, 4.152 - 23.275+22.123))
=63.491

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=78.802 - 1.33 - ( 16.122 - max(0, 2.999 - 17.238+16.122))
=63.233

Note: The Operating Income data used here is four times the quarterly (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Neola Medical AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-10.08/( ( (0.228 + max(-3, 0)) + (0.215 + max(-2.561, 0)) )/ 2 )
=-10.08/( ( 0.228 + 0.215 )/ 2 )
=-10.08/0.2215
=-4,550.79 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1.152 + 0 + -3.5527136788005E-15) - (0 + 0 + 4.152)
=-3

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.438) - (1.33 + 0 + 1.669)
=-2.561

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Neola Medical AB's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-11.093/58.123
=-19.09 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neola Medical AB EBIT Related Terms

Neola Medical AB EBIT Historical Data

* Premium members only.

The historical data trend for Neola Medical AB's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neola Medical AB EBIT Chart

Neola Medical AB Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial -6.65 -10.39 -9.63 -10.06 -10.83

Neola Medical AB Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.74 -2.71 -3.03 -2.83 -2.52

OSTO:NEOLA vs ABT, SYK, MDT: EBIT Comparison

For the Medical Devices subindustry, Neola Medical AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neola Medical AB EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Neola Medical AB's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Neola Medical AB's EV-to-EBIT falls into.


OSTO:NEOLA
29GF Score
Neola Medical AB OSTO:NEOLA
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neola Medical AB EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-11.09 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of kr-11.09 Mil mean?
Neola Medical AB (OSTO:NEOLA) has a EBIT of kr-11.09 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Neola Medical AB.
Is Neola Medical AB's EBIT too high?
Neola Medical AB's current EBIT is kr-11.09 Mil. Overall, Neola Medical AB has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Neola Medical AB's EBIT compare to ABT and SYK?
Neola Medical AB's EBIT of kr-11.09 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Neola Medical AB. Neola Medical AB's current EBIT is kr-11.09 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neola Medical AB stock overvalued right now?
Neola Medical AB (OSTO:NEOLA) has a current EBIT of kr-11.09 Mil. The current EBIT is kr-11.09 Mil. Neola Medical AB's overall GF Score™ is 29/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Neola Medical AB (OSTO:NEOLA), the current EBIT is kr-11.09 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neola Medical AB Business Description

Address Scheelevagen 27, Ideon Science Park, Gateway 9th fl oor, Lund, SWE, 223 63
Neola Medical AB is revolutionizing neonatal intensive care with NEOLA, a medical device that can offer continuous lung monitoring and real-time alerts of life-threatening complications using a technology that measures lung volume changes and oxygen gas concentration. NEOLA has the potential to provide care, fewer days in intensive care, and healthier lives for preterm born infants. The company is building on a historic Swedish legacy of medical technology innovation and invaluable contributions to health care.
29GF Score

Get the complete analysis for OSTO:NEOLA

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.92
Price